Galmed Pharmaceuticals (GLMD) Current Deferred Revenue (2016 - 2017)
Galmed Pharmaceuticals (GLMD) recorded quarterly Current Deferred Revenue of $538000.0 in Q4 2017, down 50.82% quarter-over-quarter from $1.1 million in Q4 2016, and down 50.82% on a YoY basis from $1.1 million in Q4 2016.
Galmed Pharmaceuticals (GLMD) Current Deferred Revenue (2016 - 2017) Analysis & Trends
Galmed Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $538000.0 for Q4 2017.
- In Q4 2017, Current Deferred Revenue fell 50.82% year-over-year to $538000.0; the TTM figure through Dec 2017 stood at $538000.0 (down 50.82% YoY), while the FY2017 annual figure was $538000.0, down 50.82% from the prior year.
- Current Deferred Revenue was $538000.0 for Q4 2017 at Galmed Pharmaceuticals, down from $1.1 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.1 million in Q4 2016 to a low of $538000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 538,000.00 |
| Dec 31, 2016 | 1.09 Mn |